Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Inks Target Validation, Data-Sharing Deal with Bristol-Myers Squibb

Premium

Tekmira Pharmaceuticals said this week that it has signed a four-year target-validation deal with drug maker Bristol-Myers Squibb.

Under the deal, Bristol-Myers Squibb will use siRNAs formulated with Tekmira's stable nucleic acid-lipid particle-based delivery technology to "validate the function of certain cellular targets," the companies said.

Notably, Bristol-Myers Squibb will conduct the preclinical validation work, but has agreed to share the data it generates with Tekmira, which is free to use the data to develop RNAi-based drugs against the targets.

Tekmira will receive $3 million upfront, and is responsible for providing "a pre-determined number of the SNALP batches over the four-year agreement," the firms said. "Bristol-Myers Squibb will have a first right to negotiate a licensing agreement on certain RNAi products developed by Tekmira that evolve from gene targets" it validates.

Additional terms were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.